Sign In

Aron Knickerbocker

Chief Executive Officer at Aulos Bioscience

Aron Knickerbocker is a highly accomplished executive with a strong educational background and a wealth of experience in the biotech and pharmaceutical industries.

He holds a Master of Business Administration in Business from the University of Michigan and also studied Business Administration and Management at the Stephen M. Ross School of Business.

Additionally, Aron Knickerbocker pursued a Bachelor's degree in Biology from Washington University in St. Louis, showcasing his multidimensional expertise.

Throughout his career, Aron Knickerbocker has held several key leadership positions, including Chief Executive Officer at Aulos Bioscience and board member roles in various organizations.

He has had pivotal roles in renowned companies like Five Prime Therapeutics, Inc., where he served as President, Chief Operating Officer, Chief Business Officer, Vice President of Business Development, and Director on the Board of Directors.

Aron Knickerbocker's professional journey also includes significant roles at Genentech, Alza Corporation, Amgen, Bristol-Myers Squibb, and Rayzebio, where he held the titles of Chairman, Chief Executive Officer, and Co-Founder.

Highlights

Sep 15 · linkedin

For almost the last decade and a half of my career, I’ve devoted myself to building and starting small biotech companies working to make a big difference in cancer. It was cancer that took my mom’s life too early at age 58, and it affects millions of patients and their families every year. I’m gratified that a company I cofounded in our spare bedroom/home office during the height of the COVID pandemic is now public through today’s IPO. When we were in start-up mode, my cofounders, Deborah Charych, Ph.D. and Aaron Kantoff, and I worked diligently and without pay as we crafted a new company simply out of bold new ideas and a strong drive to do something significant in targeted radiotherapy for cancer. We were at the start of a new wave to use different isotopes, employ novel targeting technology, and pursue tumor targets not yet addressed by radiopharmaceuticals. Now it is great to see this next stage in the company's development, and huge congratulations to Ken Song, Arvind Kush, and the entire RayzeBio team and board on a successful IPO! I hope many lives will be extended and saved by the new medicines to come.

#cancer #innovation #science #biotech #RayzeBio

Aron Knickerbocker
Add to my network

Location

San Francisco Bay Area